58
https://pubmed.ncbi.nlm.nih.gov/38116418
A new series of benzothiazole-based inhibitors of the mitochondrial enzyme 17β-HSD10 with nanomolar potency and low cytotoxicity have been developed, demonstrating potential for the treatment of Alzheimer’s disease and other pathologies.